Anuh Pharma LimitedANUHPHRCorporate

Pharmaceuticals - Indian - Bulk Drugs Latest results: Dec 2025 1 quarters of data

₹82.57

MCap ₹828 Cr

Anuh Pharma Limited — Stock analysis & AI research Anuh Pharma Limited — Multibagger AI analysis Anuh Pharma Limited — Seasonality — best & worst months Anuh Pharma Limited — Technical setup — score, trend, support & resistance Anuh Pharma Limited — Live exchange announcements

📋 Debt Free Stocks 📋 Promoters Increasing Stake 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹197 Cr

Sales · Dec 2025

₹17 Cr

Operating Profit · Dec 2025

8.5%

OPM % · Dec 2025

₹13 Cr

Net Profit · Dec 2025

₹1.34

EPS · Dec 2025

📝 Anuh Pharma Limited — results explained

Quarter ended December 2025 (Q3 FY26)

Anuh Pharma Limited reported revenue of ₹197 crore for the quarter ended December 2025 (Q3 FY26).

Net profit stood at ₹13 crore. Earnings per share (EPS) came in at ₹1.34.

Operating profit stood at ₹17 crore — an operating margin (OPM) of 8.5%.

Valuation snapshot

At the current price of ₹82.57, ANUHPHR has a market capitalisation of ₹828 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs industry, it is the 6th-largest of the 11 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 71.80%, foreign institutional investors (FIIs) 0.01%, public shareholders 28.19% of Anuh Pharma Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹828 Cr

Current Price ?

₹82.6

P/E ?

N/A

Industry P/E ?

32.10

P/B ?

2.35

P/S ?

N/A

P/FCF ?

-75.23

Enterprise Value ?

₹828 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

16.0%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹197 Cr

PAT — latest qtr ?

₹13 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹0 Cr

Debt to Equity ?

0.00

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

71.80%

Change in promoter holding ?

1.89%

Pledged percentage ?

N/A

Market

Return 3 months ?

4.5%

Return 6 months ?

-0.4%

🗓️ Quarterly results (1 quarters · ₹ Cr)

same fiscal quarter as Dec bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Dec 2025	YoY %	QoQ %
Sales	197	—	—
Operating Profit	17	—	—
Other Income	4	—	—
Interest	0	—	—
Depreciation	3	—	—
Profit Before Tax	18	—	—
Net Profit	13	—	—
EPS	1.34	—	—
OPM %	8.5%	—	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	25	25	25	50	+100.0%
Reserves	216	266	301	302	+0.3%
Borrowings	1	3	11	0	-100.0%
Other Liabilities	163	152	170	205	+20.6%
Total Liabilities	405	446	507	557	+9.9%
Fixed Assets	53	49	58	57	-1.7%
CWIP	-0	0	0	-0	—
Investments	91	97	106	84	-20.8%
Other Assets	261	300	342	416	+21.6%
Total Assets	405	446	507	557	+9.9%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
CFO/OP	130%	42%	78%	17%	-78.2%
Cash from Operating Activity	54	13	37	-3	-108.1%
Cash from Investing Activity	-43	1	-20	18	+190.0%
Cash from Financing Activity	-12	-9	-5	-26	-420.0%
Net Cash Flow	-2	5	12	-12	-200.0%
Free Cash Flow	52	8	17	-11	-164.7%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	118	107	119	113	-5.0%
Inventory Days	66	57	54	90	+66.7%
Days Payable	139	105	115	114	-0.9%
Cash Conversion Cycle	46	58	59	89	+50.8%
Working Capital Days	61	69	68	114	+67.6%
ROCE %	19%	26%	17%	16%	-5.9%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	% Chg
Promoters	69.91%	71.81%	71.81%	71.79%	71.80%	+0.0%
FIIs	0.04%	0.00%	0.00%	0.05%	0.01%	-80.0%
DIIs	0.00%	0.00%	0.00%	0.00%	—	—
Public	30.04%	28.19%	28.17%	28.14%	28.19%	+0.2%
No. of Shareholders	24,257	28,250	27,889	27,425	27,484	+0.2%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs · 11 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SMSPHARMA SMS Pharmaceuticals	₹442.45	4,144	39.7	898	102	19.3%	11.4%	13.3%	48.6%	5.6%	-1.4%
2	AARTIDRUGS Aarti Drugs	₹428.30	3,909	20.5	2,678	191	12.4%	7.1%	7.5%	16.3%	18.9%	-7.2%
3	HIKAL Hikal	₹229.83	2,834	—	1,734	-34	13.4%	-2.0%	-8.0%	-154.4%	6.0%	67.0%
4	BETA Beta Drugs	₹2,064.90	2,084	37.5	513	57	20.5%	11.2%	—	—	25.5%	31.7%
5	NGLFINE NGL Fine-Chem	₹2,786.60	1,722	30.1	536	57	15.6%	10.6%	36.0%	123.2%	33.6%	99.1%
6	ANUHPHR Anuh Pharma	₹92.99	932	21.1	779	44	8.6%	5.7%	16.5%	-12.8%	4.2%	42.8%
7	INFINIUM Infinium Pharma	₹222.95	347	31.2	190	14	11.3%	7.2%	—	—	45.2%	166.7%
8	AAREYDRUGS Aarey Drugs	₹98.71	329	67.1	415	4	1.6%	1.0%	-0.4%	12.3%	-56.3%	-25.3%
9	PAR Par Drugs	₹128.90	159	10.9	109	14	18.3%	13.3%	2.7%	-1.9%	20.1%	41.6%
10	KREBSBIO Krebs Biochemicals	₹57.94	125	—	25	-14	-10.0%	-55.9%	-45.2%	37.1%	27.4%	53.3%
11	VILINBIO Vilin Bio	₹18.00	27	14.2	42	2	7.6%	4.6%	—	—	215.9%	1680.0%

❓ Frequently asked questions

What was Anuh Pharma Limited's revenue in Q3 FY26?